2016
The incidence of adverse pathologic characteristics in small renal masses as size increases.
Nawaf C, Rosoff J, Adeniran A, Humphrey P, Shuch B. The incidence of adverse pathologic characteristics in small renal masses as size increases. Journal Of Clinical Oncology 2016, 34: 596-596. DOI: 10.1200/jco.2016.34.2_suppl.596.Peer-Reviewed Original ResearchAdverse pathologic featuresRenal cell carcinomaActive surveillanceLymphovascular invasionPathologic featuresRenal massesAdverse pathologic characteristicsCT1a renal massesHistologic tumor necrosisRenal tumor biopsySelection of patientsSingle-institution databaseType II histologyHigh nuclear gradeTumor size categoriesSmall renal massesSignificant increaseSarcomatoid featuresPathologic characteristicsTumor sizeCell carcinomaPrimary tumorAUA guidelinesHistologic characteristicsLarge tumors
1998
Pseudohyperplastic Prostatic Adenocarcinoma
Humphrey P, Kaleem Z, Swanson P, Vollmer R. Pseudohyperplastic Prostatic Adenocarcinoma. The American Journal Of Surgical Pathology 1998, 22: 1239-1246. PMID: 9777986, DOI: 10.1097/00000478-199810000-00009.Peer-Reviewed Original ResearchConceptsCases of adenocarcinomaProstatic adenocarcinomaHyperplastic featuresNeedle biopsyProstate carcinoma growthUsual epithelial hyperplasiaProstatic needle biopsyLow Gleason scoreLow-grade carcinomaRadical prostatectomy specimensRadical prostatectomy tissueGleason pattern 2Cystic dilatationPathologic stagePrognostic implicationsTumor sizeGleason scoreHistologic gradePapillary infoldingsRadical prostatectomyUsual hyperplasiaHistologic variantsPrognostic informationProstatic carcinomaCarcinomatous foci
1997
Effect of Canarypox Virus (ALVAC)-Mediated Cytokine Expression on Murine Prostate Tumor Growth
Kawakita M, Rao G, Ritchey J, Ornstein D, Hudson M, Harmon T, Ratliff T, Humphrey P, Tartaglia J, Paoletti E. Effect of Canarypox Virus (ALVAC)-Mediated Cytokine Expression on Murine Prostate Tumor Growth. Journal Of The National Cancer Institute 1997, 89: 428-436. PMID: 9091644, DOI: 10.1093/jnci/89.6.428.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAvipoxvirusB7-1 AntigenCytokinesDisease Models, AnimalFlow CytometryGene Expression Regulation, NeoplasticGene Expression Regulation, ViralGene Transfer TechniquesGenetic VectorsImmunotherapyInterferon-gammaInterleukin-2MaleMiceMice, Inbred C57BLMice, SCIDProstatic NeoplasmsTime FactorsTumor Necrosis Factor-alphaConceptsRM-1 cellsTumor cell expressionMouse prostate cancer cellsIL-2TNF-alphaC57BL/6 miceProstate cancer cellsTumor growthCell expressionTumor sizeB7-1Gene product expressionCo-stimulatory molecules B7-1Canarypox virusCytotoxic T lymphocyte activityKaplan-Meier survival methodMeasurable tumor sizeNonspecific antitumor activitySubsequent tumor challengeT lymphocyte activityCancer cellsCytotoxic T cellsInfected cellsProstate tumor growthMouse prostate tumor model
1995
Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues
Humphrey P, Baty J, Keetch D. Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. Cancer 1995, 75: 1842-1849. DOI: 10.1002/1097-0142(19950401)75:7+<1842::aid-cncr2820751614>3.0.co;2-2.Peer-Reviewed Original ResearchSerum prostate-specific antigenProstate-specific antigenPSA densityNeedle biopsy findingsPositive biopsy resultsHistologic gradeNeedle biopsyBiopsy findingsHistopathologic featuresTumor sizeBiopsy resultsProstate cancerPretreatment serum prostate-specific antigenSpecific antigenWhole glandAggressive prostate cancerPercentage of carcinomaRadical prostatectomy specimensRadical prostatectomy tissueWhole prostate glandBiopsy featuresPathologic stageDifferentiated tumorsProstatic carcinomaTumor grade
1994
Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer
Marks J, Humphrey P, Wu K, Berry D, Bandarenko N, Kerns B, Iglehart J. Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer. Annals Of Surgery 1994, 219: 332-341. PMID: 7909221, PMCID: PMC1243148, DOI: 10.1097/00000658-199404000-00002.Peer-Reviewed Original ResearchConceptsHER-2/neuEarly-stage breast cancerStage breast cancerHER-2/neu oncogeneBreast cancerPrognostic valueHER-2/neu proteinNeu oncogeneGenetic abnormalitiesDuke University Medical CenterFailure-free survivalProgesterone receptor contentCohort of patientsLimited prognostic valueIndependent prognostic valueShorter survival timeParaffin-embedded specimensUniversity Medical CenterHER-2/neu geneOverexpression of p53Common genetic abnormalityNodal statusRetrospective cohortLow estrogenTumor size